Tags : Tecentriq

Roche Presents New P-III Data of Tecentriq in Triple-Negative Breast

Shots: Roche divulges results from three P-III studies of Tecentriq (atezolizumab) clinical development program in TNBC at the ESMO Virtual Congress 2020. The P-III IMpassion031 assessing Tecentriq + CT vs PBO + CT demonstrated improvement in pathological complete response (pCR: 57.6% vs 41.1%) in early TNBC patients The P-III IMpassion130 study assessing Tecentriq + nab-paclitaxel […]Read More

Roche to Present its Oncology Portfolio at the ESMO Virtual

Shots: Roche highlights data from three P-III studies across the Tecentriq (atezolizumab) TNBC programme, CNS efficacy data from integrated analyses of the pivotal Rozlytrek (entrectinib) clinical development program, and the data from the registrational P-I/II ARROW trial assessing Gavreto (pralsetinib) for RET-mutant MTC patients Data from the P-III IPATential150 study in mCRPC patients and whose […]Read More

Roche’s Tecentriq + Cotellic and Zelboraf Receives the US FDA’s

Shots: The approval is based on P-III IMspire150 study assessing Tecentriq (atezolizumab) + Cotellic  (cobimetinib) + Zelboraf (vemurafenib) vs  PBO + Cotellic +   Zelboraf in patients with BRAF V600 mutation-positive advanced melanoma Results: mPFS (15.1 vs 10.6mos.); the safety profile of the Tecentriq combination was consistent with the known safety profiles of the individual medicines. […]Read More

Roche Expands its Collaboration with Immunomedics to Evaluate Tecentriq Based

Shots: The companies extend their existing collaboration to evaluate Immunomedics’ Trodelvy (sacituzumab govitecan-hziy) in combination with Tecentriq (atezolizumab) in patients with mUC and mNSCLC. The partners have ongoing collaboration in 1L metastatic triple-negative BC Roche will conduct two P-Ib/II studies utilizing MORPHEUS platform. The MORPHEUS-mUC study will evaluate Tecentriq + Trodelvy vs Tecentriq as monothx. […]Read More

Roche Reports Results of Tecentriq in P-III IMagyn050 Study for

Shots: The P-III IMagyn050 study involves assessing of Tecentriq + Avastin, paclitaxel, and carboplatin vs PBO + Avastin, paclitaxel and carboplatin in the ratio (1:1) in women with Stage III or IV ovarian cancer who are undergoing neoadjuvant or adjuvant therapy The study did not meet its 1EP i.e. PFS while the safety data were consistent […]Read More

Roche’s Tecentriq Receives the US FDA’s Approval as 1L Monotherapy

Shots: The US FDA has approved Tecentriq (atezolizumab) as a 1L Treatment for adults with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells or PD-L1 stained tumor-infiltrating covering ≥ 10% of the tumor area), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations […]Read More